F. Hoffmann-La Roche Ltd: New data for Roche s Hemlibra reinforce safety profile in people with haemophilia A
IIIb
haemophilia
Hemlibra
1
STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with
haemophilia
Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds
1
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra (emicizumab), consistent with the phase III HAVEN clinical programme.
1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International
Apheresis Equipment Market is expected to reach US$ 3,528 44 Mn CAGR of 6 9% from 2019-2027
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Plasma Fractionation Market Competitor Landscape, Regional Outlook Analysis , Forecast till 2027
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Plasma Fractionation Market 2025 | Urgent Need to Treat Hemophilia Benefits Companies in Plasma Fractionation Market, Says Fairfield Market Research
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Africa should strengthen health systems for improved prevention
29
and control of NCDS
Haemophilia also spelled hemophilia is a mostly inherited genetic disorder that impairs the body s ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints-
-or the brain. Those with a mild case of the disease may have symptoms only after an accident or during surgery. Bleeding into a joint can result in permanent damage while bleeding in the brain can result in long term headaches, seizures, or a decreased level of consciousness.